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ABSTRACT 
Introduction: Surgical aortic valve replacement (AVR) is the current gold standard treatment for symptomatic aortic 
stenosis. Without surgical intervention, patients experience a period of rapid clinical worsening, with 50% mortality 
within two years. However AVR in itself carries considerable risk and many patients may be considered too high 
risk and therefore not candidates for surgery. Transcatheter Aortic Valve implantation (TAVI) was conceived in 2002 
which showed comparable results to AVR in patient are at high surgical risk. TAVI is indicated for high risk patients 
and in patients that are contraindicated to surgery. Due to increasing public interest there is demand for TAVI to 
be used within lower risk patients. This is currently being assessed through the large SURTAVI and PARTNER A 
trials. 
Aim: The aim of this review is to appraise the current indications surrounding the use of TAVI in potentially low-
moderate surgical risk patients and inform its readers about the history of TAVI and its future direction. This paper 
also addresses the pathogenesis, epidemiology, management and prognosis of aortic stenosis from the most up 
to date research studies. 
Methods: A systematic review was conducted. Databases searched included MEDLINE, Embase, AMED, Science 
Direct, UPTODATE and the British Journal of Cardiology for papers published from the period of January 1990-
present. Combinations of the following terms were used: ‘tavi, ‘transcatheter aortic valve implantation’, ‘aortic 
stenosis’, ‘treatment of aortic stenosis’, ‘aortic valve replacement’ ‘avr’ ‘Medtronic core valve’ ‘bioprosthetic heart 
valves’, ‘edward sapien  bioprostheis’ and ‘treatment of aortic stenosis’. All papers were from the most up to date 
sources and all information was cross referenced with NICE guidelines and the UPTODATE database. 
Results: 37 papers were selected for review. The main findings included: the incidence of aortic stenosis is rising 
due to advances in medical treatment resulting in an aging population; AVR is the current gold standard treatment 
for aortic stenosis; TAVI is superior to medical therapy alone; TAVI is indicated in high surgical risk patients and 
those that are contraindicated to surgery; TAVI is comparable to AVR in high risk patients; studies have shown 
comparable result comparing TAVI with AVR in low- moderate risk pateints; the wide SURTAVI and PARTNER A 
trials are currently assessing the use of TAVI in low-moderate risk patients. 
Conclusions: TAVI has revolutionized an alternative way of thinking towards the management of symptomatic aortic 
stenosis. TAVI is indicated in patient whom are at high surgical risk and in cases where surgery is contraindicated. 
AVR remains the gold standard treatment in low-moderate surgical risk patients. TAVI may be considered as an 
alternative method to surgical AVR following the results of the PARTNER 2 and SURTAVI trials. 
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Introduction 
Surgical aortic valve replacement (AVR) is the 
current “gold standard” treatment for symptomatic 
aortic stenosis. Without surgical intervention, 
patients experience a period of rapid clinical 
decline, with 50% mortality within 2 years. However 
AVR in itself carries considerable risk and many 
patients may be considered too high risk for surgery. 
Until recently, these patients were managed with 
best medical therapy, which mildly alleviated 
symptoms but did not alter the disease’s natural 
progression. Since its introduction in 2002, 
transcatheter aortic valve implantation (TAVI) has 
offered an alternative for these patients, showing 
prognostic results comparable with AVR.  
 
Following the results of the PARTNER (Cohort B) 
study, which showed considerable reductions in 
mortality for TAVI compared with best medical 
therapy, TAVI has become the mainstay treatment 
in patients deemed too high risk for AVR. TAVI has 
recently been compared with AVR in high-risk 
patients who are surgically eligible, through the US-
PIVOTAL and PARTNER (Cohort A) trials. Both trials 
showed comparable results in both treatment 
options and TAVI has since been updated and is 
licenced as an alternative to AVR in high-risk 
patients. This paper will explore the current 
guidelines surrounding indications for TAVI and 
surgical AVR in the treatment of aortic stenosis 
based on the findings of the PARTNER (Cohorts A 
and B) and US-PIVOTAL studies. This paper will also 
appraise the type of valves used in TAVI, the best 
access points undertaken, their potential use in low- 
to moderate-risk groups, and also the main reasons 
why the population may prefer TAVI over AVR. 
 
Background 
Aortic stenosis is a chronic inflammatory and fibrotic 
process of the aortic valve resulting in abnormal 
narrowing of the aortic orifice and subsequent 
impediment of left ventricular ejection.1 It is the 
most prevalent valve-related heart disease in the 
Western world affecting 4% of the population over 
75 years of age and is one of the leading causes of 
morbidity and mortality.2 This condition has multiple 
aetiologies, the most common including senile 
calcific, bicuspid, rheumatic, and congenital.3,4 The 
most common of these is calcific aortic valve disease 




A number of mechanisms have been postulated 
regarding development of CAVD. One of these 
theories involves transformation of interstitial cells 
within the valve leaflets from a regular reparative 
state, to a more active proliferative state following 
mechanical stress or injury secondary to disease. 
When in their active state, these interstitial cells 
upregulate osteoblasts and myofibroblasts, which 
then induce calcification.6  
 
Another mechanism suggests a role for T 
lymphocytes, monocytes, and low-density 
lipoproteins in initiating inflammation and 
calcification within the aortic leaflets, following 
damage to their basement membranes through 
mechanical stress.7 Bicuspid-related aortic stenosis 
is the most prevalent cause in younger populations 
as mechanical stress exerted on the valve leaflets is 
distributed amongst two leaflets instead of three, 
thereby accelerating damage mediated via 
mechanical stress.8 These processes of calcification 
result in progressive thickening and stiffening of the 
aortic leaflets, leading to impaired leaflet motion 
and subsequent narrowing of the aortic orifice.  
 
As the aortic orifice continues to narrow, the left 
ventricle exhibits chronic resistance during systole, 
resulting in a systolic pressure gradient between the 
aorta and left ventricle.9 In an attempt to overcome 
this increase in afterload, the musculature of the left 
ventricle undergoes concentric hypertrophy.10 This 
is where the muscular walls of the left ventricle 
thicken approximately equally through the 
replication of parallel sarcomeres. This 
compensatory process strengthens left ventricular 
contraction and aids in the maintenance of stroke 
volume and cardiac output, but at the expense of 
reduced diastolic compliance.11 
 
As aortic stenosis persists, the left ventricle 
continues to hypertrophy resulting in elevation of 
left ventricular end-diastolic pressure. When this 
increase is sufficient, it evokes an equivalent 
increase in pulmonary capillary arterial pressures 
and subsequent reductions in cardiac output 
secondary to diastolic dysfunction. Cardiac output 
may be impaired further by systolic dysfunction, 
whereby myocardial elasticity and thus contractility 
are reduced as a consequence of left ventricular 
hypertrophy.12  
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Presentation 
The natural history of aortic stenosis is that of a long, 
dormant, relatively asymptomatic period, followed 
by a sharp decline in survival following the onset of 
symptoms.13 As aortic stenosis progresses, the left 
ventricle eventually succumbs to the chronically 
elevated ventricular pressures and begins to dilate. 
Ventricular dilatation reduces ejection fraction and 
cardiac output leading to symptoms of heart 
failure.14 Backwards pressure is exerted on the 
pulmonary system, leading to pulmonary venous 
hypertension, reactive pulmonary vasoconstriction, 
and dyspnoeic symptomatology. Angina and 
syncope are frequently experienced due to 
inadequate coronary blood flow and the larger 
oxygen demand of the overexerted, hypertrophied 
left ventricle. Calcific infiltrates from the aortic valve 
may extend to the conduction system resulting in 
atrial arrhythmias, atrial-ventricular blockade, and 
left bundle branch block.15 As a result, untreated 
patients with aortic stenosis are at increased risk of 
heart failure, dilated cardiomyopathy, arrhythmias, 
and sudden death. With an ageing population, 
aortic stenosis is becoming increasingly prevalent 
and represents a significant global health problem. 
 
Methods 
A systematic review of the literature was conducted. 
Databases searched included MEDLINE, Embase, 
AMED, Science Direct, UpToDate, and the British 
Journal of Cardiology for papers published from the 
period of January 1990–present. Combinations of 
the following terms were used: “tavi”, 
“transcatheter aortic valve implantation”, “aortic 
stenosis”, “treatment of aortic stenosis”, “aortic 
valve replacement”, “avr”, “Medtronic core valve”, 
“bioprosthetic heart valves”, “Edward Sapien 
bioprosthesis”, and “treatment of aortic stenosis”. 
All papers were from the most up-to-date sources 
and all information was cross-referenced with NICE 
guidelines and the UpToDate database. 
 
Surgical valve replacement 
Patients with aortic stenosis experience a rapid 
period of clinical deterioration with more than 50% 
of people dying within 2 years of symptom onset if 
surgical intervention is not initiated.16 AVR is 
currently the “gold standard” treatment for 
symptomatic aortic stenosis. However, despite 
continual improvements in operative mortality rates, 
AVR still poses considerable risk in certain patient 
subsets including the very elderly, frail, and poly-
morbid.17 This created a paradox whereby patients 
who are most in need of surgery were deemed 
inappropriate or too high risk, and were managed 
medically. This equated to approximately 30–40% 
of patients with symptomatic severe aortic stenosis 
that were not candidates for surgery.18  
 
Transcatheter aortic valve implantation  
In 2002, Cribier et al.19 established a less invasive 
alternative approach to surgical AVR in an effort to 
manage the growing unmet clinical need of high-risk 
patients ineligible for surgery. The TAVI procedure 
involves percutaneous implantation of a stent-based 
biological prosthesis into the diseased native aortic 
valve, which offers lower peri-procedural risk than 
conventional open valve replacement. There are 
currently two prostheses in wide commercial use; 
these include the self-expanding Medtronic-
CoreValve bioprosthesis and the balloon 
expandable Edwards-Sapien bioprosthesis. 
Advancement of these biological prostheses can be 
undertaken via a transfemoral, subclavian or direct 
aortic approach by means of a retrograde catheter 
or introduction of an anterograde catheter via the 
transapical route.20  
 
TAVI versus best medical therapy 
In 2010, Leon et al.21 conducted the large 
multicentre placement of aortic transcatheter valves 
(PARTNER Cohort B) trial. This trial compared the 
outcomes of best medical therapy against those of 
TAVI in patients with severe aortic stenosis who 
were too high risk for conventional AVR. The natural 
progression of aortic stenosis remained unchanged 
in the best medical therapy arm, which showed 
50.7% and 44.6% mortality rates at 1 year from any 
cause and cardiovascular causes respectively. 
Transfemoral TAVI was associated with a 20% 
reduction in mortality rates as well as reductions in 
symptoms and level of recurrent hospitalizations. 
The haemodynamic performance of the bio-
prosthetic valves was followed up 1 year post-TAVI 
with echocardiography, which revealed no signs of 
deterioration. TAVI was, however, associated with 
an increased risk of major vascular complications, 
paravalvular regurgitation and stroke.  
 
It was concluded that the higher level of vascular 
events occurred as a result of gaining percutaneous 
access with large diameter delivery catheters.22 The 
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higher levels of stroke were caused by 
atherothrombotic emboli liberated from the aortic 
valve during implantation.23 Current studies are 
therefore evaluating the use of smaller valves, 
catheters and support systems as well as devices to 
protect from cerebral emboli in an attempt to 
reduce future complications. Following results of the 
PARTNER (Cohort B) trial, TAVI has been shown to 
be a superior approach for the best medical therapy 
in patients who are too high risk or not medically fit 
for surgery.  
 
TAVI versus AVR 
Due to the promising results of the PARTNER 
(Cohort B) trial, the potential role of TAVI was further 
investigated among high-risk patients who were 
nevertheless viable candidates for surgery.  
Numerous trials including PARTNER (Cohort A)24 
and the US-PIVOTAL25 trials were initiated with the 
aim of comparing outcomes of TAVI with that of 
standard surgical AVR. PARTNER (Cohort A) 
compared outcomes using the balloon expandable 
Edwards-Sapien bioprosthesis, whereas the US-
PIVOTAL study used the self-expanding Medtronic-
CoreValve bioprosthesis. Each of these trials utilized 
both transfemoral and transapical methods and thus 
secondary outcomes included approach risk. 
 
The results of the PARTNER (Cohort A) trial showed 
comparable mortality rates at 30 days, 1 year and 2 
years for both TAVI and AVR groups, respectively. 
Patients treated with TAVI experienced quicker 
recovery times and greater amelioration of their 
symptoms but were similar to surgical patients at the 
1 and 2 year marks. There are inherent differences 
in complications between the two approaches. 
Surgical AVR was associated with higher rates of 
new-onset atrial fibrillation and life-threatening 
bleeding, whereas TAVI was associated with higher 
risk of vascular and athero-embolic complications. In 
this study, TAVI was associated with a greater risk of 
stroke, TIA, paravalvular regurgitation, and vascular 
complications at 30 days, 1 year and 2 years.26  
 
The results of the US-PIVOTAL trial showed lower 
mortality rates in the TAVI group than the AVR 
group. Periprocedural and postoperative 
complications were relatively consistent with the 
PARTNER (Cohort A) trial, reporting higher levels of 
major bleeding and new onset atrial fibrillation in 
the surgical group, with higher risk of vascular 
complications, TIAs, and stroke within the TAVI 
group. TAVI was also associated with a higher 
incidence of conduction system disruption 
necessitating permanent pacemaker implantation. 
In this trial, the risk of stroke or TIA within the first 30 
days was initially highest among the TAVI group. 
However, after this period, this risk reduced and was 
equal with the surgical group at the 1- and 2-year 
marks. This higher incidence in stroke and TIA may 
reflect the liberation of atherothrombotic debris 
from the aorta or valve during the procedure, 
resulting in embolization.27 Despite the higher 
incidence of stroke at 30 days, the composite 
mortality rate in both TAVI and surgical arms from 
major stroke or any other cause, were comparable 
amongst both groups at 30 days and 1 and 2 years. 
Following the results of these studies, TAVI is now 
licensed in patients with severe symptomatic aortic 
stenosis who are not candidates for surgery or as an 
alternative in high-risk patients.3  
 
TAVI access routes  
With regards to approach, numerous trials have 
reported significantly higher complication rates 
among transapical or subclavian access routes in 
comparison with those performed 
transfemorally.24,28,29 Patients, however, were not 
randomized beforehand and many of those who 
received transapical or subclavian approaches 
possessed higher risk profiles than those who 
underwent transfemoral approaches. Therefore, it is 
difficult to say whether the higher mortality rates 
observed in these two approaches were due to 
higher procedural risks or simply a reflection of 
these patients’ increased risk profiles. A large study 
has since adjusted for potential confounders and 
confirmed transfemoral approach as superior to 
transapical and subclavian routes, which are 
associated with increased mortality rates and 
adverse events at 30 days, 1 year and 2 years.30 The 
transfemoral approach is now the standard route 
undertaken, however both transapical and 
subclavian routes remain integral measures of the 
TAVI armamentarium where femoral access may not 
be feasible due to excessive tortuosity, peripheral 
vascular disease, or small vessel calibre.31 
 
Medtronic CoreValve versus Edwards-Sapien 
bio-prostheses 
The UK TAVI registry32 has concluded no significant 
differences in mortality rates among patients treated 
with the Edwards-Sapien or the Medtronic 
CoreValve bioprostheses. There was however a 
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higher incidence of paravalvular aortic regurgitation 
and need for permanent pacemaker implantation in 
those managed with the CoreValve system, which is 
consistent with most studies. This however has not 
equated to differences in mortality rates between 
both systems, but the need for further study 
regarding aortic regurgitation on future outcomes is 
justified.30 
 
Future of TAVI 
Due to the effectiveness of TAVI, more patients with 
symptomatic aortic stenosis classed as low to 
moderate risk are demanding percutaneous therapy 
over the well-established AVR option. There are 
many reasons why patients may prefer TAVI over 
AVR, including: quicker recovery times, reduced 
number of repeat hospital admissions, faster 
amelioration of symptoms, reduced risk of life-
threatening bleeding and new-onset atrial 
fibrillation, it is less invasive, and it avoids sternal 
scarring. Presently, TAVI has not been compared 
with AVR in patients who are of low to moderate risk 
and is therefore not indicated for this subgroup. 
Before TAVI can be recommended as an alternative 
approach to open heart surgery in lower risk 
patients, additional evidence regarding long-term 
procedural outcomes is imperative, including 
strategies to reduce complications.   
 
The long-term complications post-TAVI are 
currently unknown, with data rarely exceeding 4 
years of follow-up.33 Mortality rates, complications, 
and bio-prosthetic longevity must be established 
through longer periods of study before TAVI can be 
used in low- to moderate-risk patients. The 
established complications, such as higher rates of 
stroke, vascular events, and conduction system 
impairment should be minimized. As regards 
minimizing stroke risk, cerebral embolic protection 
devices and greater detection of possible embolic 
debris should be facilitated.34 The higher rates of 
vascular complications may decrease with future 
developments such as use of more discreet devices, 
superior screening and better closing devices.35 The 
higher level of permanent pacemaker implantation 
and aortic regurgitation, particularly in the 
Medtronic CoreValve bioprostheses should be 
addressed through enhanced device engineering, 
positioning, sizing, and dilatation post-TAVI.36 
Current guidelines recommend dual antithrombotic 
therapy post-TAVI. This is currently being evaluated 
in order to determine if only one antithrombotic 
drug would suffice, which is prudent in elderly 
patients or those on chronic anticoagulant 
regimens.37 The future usage of TAVI in low- to 
moderate-risk patients is currently being 
investigated through the PARTNER 2 and SURTAVI 
trials.38,39 These long-awaited studies will help 
evaluate the need for TAVI in low- to moderate-risk 
patients. 
 
Limitations of current literature 
There is limited data encompassing the use of TAVI 
in the low- to moderate-risk surgical patients. Only 
a few studies investigating this have been 
conducted thus far. As TAVI has only been around 
for 13 years, long-term follow up is not yet available, 
restricting discussion of long-term complications to 
conjecture. There are few studies comparing the 
current bioprosthetic valves available, their 
complications and how they compare with surgical 
AVR among patients with different surgical risk 
levels.   
 
Conclusions 
Since its conception in 2002, TAVI has 
revolutionized the approach to the management of 
symptomatic aortic stenosis. In patients who are too 
high risk for surgical AVR or where surgery is 
contraindicated, TAVI has shown superlative results 
in relation to best medical therapy. TAVI has also 
shown promise amongst high-risk patients who are 
eligible for surgery, demonstrating comparable 
outcomes in terms of mortality. As a result, TAVI is 
now considered in patients where surgery is not 
appropriate and also in patients with high surgical 
risk. Despite the recent success of TAVI, AVR 
remains the “gold standard” treatment in low- to 
moderate-risk patients. Due, in part, to its minimally 
invasive approach, TAVI may well become a logical 
alternative among low- to moderate-risk patients, 
however longer follow-up studies are a necessity. 
Despite future innovations, one absolute is the need 
for a multidisciplinary approach, where every case is 
taken on its own merit and managed as such.   
 
With continual improvements in engineering, 
patient selection, techniques and pending the 
results of the zealously anticipated PARTNER 2 and 
SURTAVI trials, a paradigm shift in the management 
of symptomatic aortic stenosis may be closer than 
we thought. Surgical AVR may ultimately be utilized 
in patients only when TAVI is contraindicated.  
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Summary points 
•   TAVI has revolutionized the approach to the 
management of symptomatic aortic stenosis.  
•   TAVI is indicated in patients at high surgical 
risk and in cases where surgery is 
contraindicated 
•   AVR remains the “gold standard” treatment in 
patients with low to moderate surgical risk. 
•   TAVI may be considered as an alternative 
method to surgical AVR following the results of 
the PARTNER 2 and SURTAVI trials. 
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